What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

doi:10.1111/j.1365-2893.2012.01613.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

Journal of viral hepatitis - 1 May 2013

Ahmed F

Abstract excerpt

Summary. Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Both of these concerns are of particular relevance in Pakistan.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Developing Countries
Share to Health Services Accessibility
Share to Hepacivirus
Share to Hepatitis C, Chronic
Share to Oligopeptides
Share to Pakistan
Share to Proline

Source

Open in PubMed

Identifiers

PMID: 23565620
DOI: 10.1111/j.1365-2893.2012.01613.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics